Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 1.00 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | GFER | P55789 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | KHK | P50053 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5207748 | 0.82 | EPHX2 (0.69) | EPHX2MAPTALDH1A1ROCK1 | |
| SCHEMBL7631574 | 0.81 | EPHX2 (0.68) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL8496442 | 0.80 | EPHX2 (0.67) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL7238788 | 0.79 | USP8 (0.65) | EPHX2MAPTGAAALDH1A1 | |
| SCHEMBL7234775 | 0.79 | EPHX2 (0.64) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL14409313 | 0.78 | EPHX2 (0.62) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL7240124 | 0.77 | EPHX2 (0.63) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL8495561 | 0.76 | EPHX2 (0.61) | EPHX2MAPTGAAALDH1A1 | |
| SCHEMBL6991668 | 0.76 | RAB9A (0.62) | EPHX2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL7234788 | 0.76 | EPHX2 (0.61) | EPHX2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563088-A | Novel use of inhibitors of soluble epoxide hydrolase | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | CN | claimed |
| EP-2091542-A1 | NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. Hoffmann-Roche AG (CH) | 2009-08-26 | — | — | EP | claimed |
| US-20090082402-A1 | Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase | ROCHE PALO ALTO LLC | 2009-03-26 | — | — | US | claimed |
| WO-2008074678-A1 | NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | claimed |
| EP-1406892-B1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2007-09-05 | — | — | EP | claimed |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | 2004-05-13 | — | — | US | claimed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | claimed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | claimed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2000023060-A2 | METHOD OF TREATING IMMUNOLOGICAL DISORDERS MEDIATED BY T-LYMPHOCYTES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| CN-101563088-A | Novel use of inhibitors of soluble epoxide hydrolase | HOFFMANN LA ROCHE (CH) | 2009-10-21 | — | — | CN | disclosed |
| EP-2091542-A1 | NOVEL USE OF INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. Hoffmann-Roche AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-20090082402-A1 | Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase | ROCHE PALO ALTO LLC | 2009-03-26 | — | — | US | disclosed |
| US-20090082402-A1 | Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase | ROCHE PALO ALTO LLC | 2009-03-26 | — | — | US | disclosed |
| EP-1406892-A1 | PHENYL PYRAZOLE DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-30 | — | — | US | disclosed |
| US-6506747-B1 | Method of treating an inflammatory disease which comprises administering to a patient in need of such treatment-a N-(4-(5-Ethyl-3-pyridin-3-yl-pyrazol-1-yl)phenyl)pyridine-3-carboxamide; | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| WO-2003002555-A1 | METHODS OF USING SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| WO-1999062885-A1 | SUBSTITUTED 1-(4-AMINOPHENYL)PYRAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022929-A1 | Method of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885RAB9A 3716/4885SMN1; SMN2 3759/4885 |
| US-20090082402-A1 | Methods of treating genitourinary disorders using inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, FOLH1 | EPHX2 2/4885RAB9A 3600/4885SMN1; SMN2 2235/4885 |
| US-20040092567-A1 | Methods of using soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885RAB9A 4054/4885SMN1; SMN2 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.